Showing 1 to 1 of 1 results
theglobeandmail.com
🌐 75% Global Worthiness
Eli Lilly Exceeds Profit Forecasts Despite Sales Disappointments
Eli Lilly, exceeding analysts' expectations, forecasts higher-than-expected annual profit despite recent sales misses for its Mounjaro and Zepbound drugs; the company's stock rose 1 percent in premarket trading.
Eli Lilly Exceeds Profit Forecasts Despite Sales Disappointments
Eli Lilly, exceeding analysts' expectations, forecasts higher-than-expected annual profit despite recent sales misses for its Mounjaro and Zepbound drugs; the company's stock rose 1 percent in premarket trading.
Progress
36% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results